Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib in primary warm autoimmune hemolytic anemia
ISRCTN14903256Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing Parsaclisib with Placebo followed by parsaclisib (2 arms). Primary endpoint: Durable hemoglobin response. Started Aug 2021; status: active, not recruiting.
02
Drugs
parsaclisib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on ISRCTN14903256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14903256.